Small Molecules

21 Aug 2017 Alkermes Initiates Rolling Submission of ALKS 5461 New Drug Application for Major Depressive Disorder
21 Aug 2017 Ironwood Pharmaceuticals Announces FDA Approval of DUZALLO® (lesinurad and allopurinol) for the Treatment of Hyperuricemia in Patients with Uncontrolled Gout
21 Aug 2017 Ovid Therapeutics Announces First Patient Randomized in Phase 1b/2a Clinical Trial of TAK-935/OV935 in Adults with Rare Epilepsies
21 Aug 2017 New XARELTO® (rivaroxaban) Data at ESC Congress 2017 Includes Late-Breaking Results from Landmark Phase 3 COMPASS Study
21 Aug 2017 Saniona AB: Saniona's partner, Medix, initiates Phase 3 study for tesofensine in obesity
21 Aug 2017 Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria
20 Aug 2017 Mithra announces first subject completes ESTELLE® phase III study
18 Aug 2017 Medivir initiates clinical study of birinapant in combination with KEYTRUDA® (pembrolizumab) in patients with treatment-refractory solid tumours
18 Aug 2017 Lynparza receives additional and broad approval in the US for ovarian cancer
17 Aug 2017 Trovagene's PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy
17 Aug 2017 PolyPid Ltd. Completes Enrollment in Phase Ib/II Study of D-PLEX™ in Post-Cardiac Surgery Sternal Infection
17 Aug 2017 Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency
17 Aug 2017 Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (cabozantinib) for the Treatment of Previously Untreated Advanced Kidney Cancer
16 Aug 2017 FDA Accepts Medivir´s IND Application for MIV-711, Enabling Clinical Development in the US
15 Aug 2017 ONC201 Trial for Neuroendocrine Cancer Begins at Cleveland Clinic
15 Aug 2017 Saniona AB: Saniona's partner, Luc Therapeutics, nominates clinical candidate and initiates preclinical development in joint Ataxia program
15 Aug 2017 Amarin's REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at Recommendation of Independent Data Monitoring Committee
15 Aug 2017 Zynerba Pharmaceuticals Announces that Results from Phase 2 STOP Trial Support Continued Development of ZYN002 in Osteoarthritis
15 Aug 2017 Conatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis
15 Aug 2017 Spectrum Pharmaceuticals Announces Initiation of the Registrational Phase 3 Trial of Qapzola™ (apaziquone) in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)
12 Aug 2017 Achieve Announces FDA Acceptance of the Investigational New Drug Application (IND) for Cytisine as a Smoking Cessation Treatment
12 Aug 2017 Gilead Announces U.S. FDA Priority Review Designation for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
12 Aug 2017 Phase 2b Results of Viamet’s Oral VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis Presented at IDSOG Annual Meeting
11 Aug 2017 KemPharm Announces Preliminary Results from KP415 Pharmacokinetic Single and Multiple Dose Trial
10 Aug 2017 BioSight Completed Patient Enrollment and Treatment in its Extended Acute Leukemia Phase I/II Clinical Trial with BST-236, a Novel Cytarabine Pro-Drug

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing